RESEARCH ARTICLE

Cholinergic-like neurons carrying PSEN1 E280A mutation from familial Alzheimer’s disease reveal intraneuronal sAPPβ fragments accumulation, hyperphosphorylation of TAU, oxidative stress, apoptosis and Ca\(^{2+}\) dysregulation: Therapeutic implications

Viviana Soto-Mercado, Miguel Mendivil-Perez, Carlos Velez-Pardo, Francisco Lopera, Marlene Jimenez-Del-Rio*

Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, University of Antioquia (UdeA), SIU Medellin, Medellin, Colombia

* marlene.jimenez@udea.edu.co

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive memory loss and cognitive disturbance as a consequence of the loss of cholinergic neurons in the brain, neuritic plaques and hyperphosphorylation of TAU protein. Although the underlying mechanisms leading to these events are unclear, mutations in presenilin 1 (PSEN1), e.g., E280A (PSEN1 E280A), are causative factors for autosomal dominant early-onset familial AD (FAD). Despite advances in the understanding of the physiopathology of AD, there are no efficient therapies to date. Limitations in culturing brain-derived live neurons might explain the limited effectiveness of AD research. Here, we show that mesenchymal stromal (stem) cells (MSCs) can be used to model FAD, providing novel opportunities to study cellular mechanisms and to establish therapeutic strategies. Indeed, we cultured MSCs with the FAD mutation PSEN1 E280A and wild-type (WT) PSEN1 from umbilical cords and characterized the transdifferentiation of these cells into cholinergic-like neurons (ChLNs). PSEN1 E280A ChLNs but not WT PSEN1 ChLNs exhibited increased intracellular soluble amyloid precursor protein (sAPPβ) fragments and extracellular Aβ42 peptide and TAU phosphorylation (at residues Ser202/Thr205), recapitulating the molecular pathogenesis of FAD caused by mutant PSEN1. Furthermore, PSEN1 E280A ChLNs presented oxidative stress (OS) as evidenced by the oxidation of DJ-1Cys\(^{106}\)-SH into DJ-1Cys\(^{106}\)-SO\(_3\) and the detection of DCF-positive cells and apoptosis markers such as activated pro-apoptosis proteins p53, c-JUN, PUMA and CASPASE-3 and the concomitant loss of the mitochondrial membrane potential and DNA fragmentation. Additionally, mutant ChLNs displayed Ca\(^{2+}\) flux dysregulation and deficient acetylcholinesterase (AChE) activity compared to control ChLNs. Interestingly, the inhibitor JNK SP600125 almost completely blocked TAU phosphorylation. Our findings demonstrate that FAD MSC-derived cholinergic neurons with the
PSEN1 E280A mutation provide important clues for the identification of targetable pathological molecules.

**Introduction**

Alzheimer’s disease (AD) is a chronic neurodegenerative condition characterized by loss of memory, reasoning and decision-making functions [1] due to the severe loss of cholinergic neurons from the nucleus basalis magnocellularis of Meynert and cholinergic projections to the cortex and hippocampus [2]. The neuropathological profile of AD is associated with the extracellular accumulation of insoluble forms of amyloid-β (Aβ) in plaques and intracellular aggregation of the microtubule protein TAU in neurofibrillary tangles [3]. Aβ is derived by the proteolytic cleavage of amyloid β precursor protein (APP). The full length APP is first cleaved by β-secretase (BACE1) freeing a soluble proteolytic fragment, recognized as soluble APPβ (sAPPβ). The remaining C-terminal membrane bound APP fragment, CTFβ or C99 fragment, undergoes additional cleavages by γ-secretase to generate a series of peptides prone to aggregation [4]. Interestingly, both hAPP and Aβ species have been shown to aggregate intracellularly [5–7]. Most mutations in the presenilin 1 (PSEN1) gene, which codes for the catalytic component of γ-secretase [8], result in the overproduction of Aβ, specifically, the 42-amino acid Aβ1–42 isoform (Aβ42, hereafter Aβ) [9], and occur most frequently in familial AD (FAD; http://www.molgen.ua.ac.be/ADMutations/). Glu280Ala (p. E280A, c.839A>C, exon 8) in PSEN1 is a well-characterized FAD mutation found in a large kindred localized in Antioquia, Colombia [10–13] that shows typical phenotypes of AD with complete penetrance [14]. Similar to the majority of dominant-negative PSEN1 mutations [15, 16], PSEN1 E280A produces increased Aβ42 deposition [17], hippocampal neuron loss [18], and Aβ/TAU accumulation in young adults [19, 20].

Despite advances in the understanding of the physiopathology of AD [21], there are no efficient therapies to date. Although limitations in culturing brain-derived live neurons might slow AD research, the rapid advances in cellular genetic reprogramming, in particular the induction of somatic cells (e.g., fibroblast) into stem cells (e.g., human induced pluripotent stem cells, hiPSCs), has led to the modeling of FAD PSEN1 mutations in vitro [22–25]. Obtaining iPSCs from patients bearing PSEN1 mutations is appealing; however, the isolation and purification procedures are technically challenging, expensive, time consuming and labor intensive. Alternatively, the human mesenchymal stromal (stem) cells derived from Wharton’s jelly tissue (WJ-MSCs) are multipotent cells that can differentiate and/or transdifferentiate into mesodermal and ectodermal lineage cells [26–29]. Because MSCs might be equivalent to human embryonic stem cells (hESCs) and hiPSCs [30, 31]; these cells have become an interesting and promising tool for modeling FAD PSEN1 E280A in vitro.

The aim of the present study was to establish an in vitro cellular model that reveals the major pathologic features of the FAD PSEN1 E280A mutation, thereby enabling investigation of the pathomechanisms of early onset FAD. Therefore, Aβ42 accumulation, Aβ42 production, TAU phosphorylation, oxidative stress (OS), cell death, and neuronal dysfunction were investigated in cholinergic-like neurons (ChLNs) derived from wild-type (control) and PSEN1 E280A MSCs. We demonstrate for the first time that FAD PSEN1 E280A pathology can be recapitulated in MSC-derived ChLNs. These findings in ChLNs show great promise for modeling human FAD in vitro and identifying therapeutic targets for AD treatment.
Materials and methods

The collection and use of umbilical cords from newborns was approved by Ethics Committee of the Hospital San Vicente Fundacion Research act # 13–2015 Colombia, and was provided following natural childbirth with written consent. Donors had a familial background of AD. The mother’s medical history was negative for human pathogens, such as human immunodeficiency virus 1/2, hepatitis B and C virus, and syphilis. The cord (~7 cm long) was immersed in low-glucose DMEM (Sigma) supplemented with 100 U Penicillin/streptomycin (Sigma) and 5 μg/ml Plasmocin (Invivogen) and immediately transported to the laboratory.

Isolation and expansion of hWJ-MSCs

The human umbilical cords were obtained from ten healthy, natural childbirths (Tissue Bank Code (TBC) # WJMSC-11, -12, -13, -14, -15, -16, -17, -18, -19, -20) and aseptically stored at 4 ºC PBS containing 1% penicillin and streptomycin. The cords were rinsed several times to drain blood from vessels, cut into 2–3-cm-long segments and rinsed again. Umbilical arteries and veins were removed, and the remaining tissue was transferred to a sterile container and chopped into small fragments in PBS. The explants were digested with an enzyme mixture containing 0.25% trypsin, 0.1% Dispase and 0.5% collagenase II for 2 h at 37 ºC under constant agitation. Then, the digestion products were centrifuged at 447 x g for 40 min, and the pellet was cultured in T75 cell culture flasks (Corning) in hWJ-MSC regular culture medium (low-glucose DMEM supplemented with 20% fetal bovine serum (FBS, Sigma), 100 U penicillin/streptomycin and 5 μg/ml Plasmocin). Once confluence had been reached, adherent cells (passage 0) were detached with 0.25% trypsin and passaged at 13,000 cells/ cm² in a T75 flask. Cells from passages 2 or 4 were harvested during the first expansion period for further characterization and cryopreservation.

Identification of the PSEN1 E280A mutation in WJMSCs

The PSEN1 E280A mutation was detected by PCR using mismatch primers and digestion of the products with Bsm1 [32]. Digested products were separated on a 3% agarose gel. According to different mobility electrophoretic patterns, samples were classified as wild-type (WT) or mutant PSEN1 E280A when compared to PSEN1 E280A carrier (positive case NeuroBank (NB) code #18233) or wild type PSEN1 genotype (NB code#18574). The TBC# WJMSC-12 (female) sample was identified for PSEN1 E280A mutation. For comparative purposes, we pre-selected female WT PSEN1 samples (TBC# WJMSC-11, -15, -17), and TBC# WJMSC-11 WT PSEN1 was randomly selected for further experiments.

APOE genotyping analysis. Genotyping of the APOE polymorphism (n = 10) was performed using polymerase chain reaction amplification of a 244-bp fragment followed by digestion with HhaI as described by [33].

Karyotyping. Karyotype analysis was performed by the Medical Genetics Unit of the Faculty of Medicine–UdeA, using standard cytogenetic protocols. At 60–70% confluence, WJMSC-11 WT and WJMSC-12 PSEN1 E280A cells were incubated with 0.1 mg/ml Colcemid (Sigma) for 90 min at 37 ºC. Then, the cells were detached with 0.25% trypsin and centrifuged at 591 x g for 20 min. The medium was removed, and the hypotonic solution (0.075 M KCl, 0.017 M Na-citrate) was added and incubated for 20 min at 37 ºC. After a new centrifugation, cells were fixed with freshly prepared Carnoy’s solution. Metaphase spreads were analyzed after staining with quinacrine (Sigma) for karyotyping. Analysis was performed on three different primary cultures counting 20 metaphases for each sample.
Colony-forming units assay
The colony formation assay is an *in vitro* cell survival assay based on the ability of a single cell to grow into a colony [34]. WJMSC-11 WT and WJMSC-12 PSEN1 E280A cells were seeded at a density of 200 cells/well on 6-well plates followed by the addition of 3 mL of regular culture medium. The cultures were left to grow in a humidified atmosphere with 5% CO$_2$ at 37 °C for 15 days. The culture medium was changed twice a week. After 15 days of cultivation, both WT and mutant PSEN-1 cells were stained with 0.5% crystal violet and counted using the cell counter plugin from ImageJ program. The experiment was conducted three times.

Immuno-phenotypic characterization
Standard flow cytometry techniques were used to determine the cell surface epitope profile (CD9, CD73, CD90, CD34 and CD45) of both WT and mutant PSEN1 MSCs. Briefly, hWJ-MSCs were incubated with saturating concentrations (1:500) of mouse monoclonal antibodies conjugated to human CD9-peridinin chlorophyll protein (PerCP)-cy5.5, CD73-phycoerythrin (PE), CD90 PE-cy5.5, CD34 PE, and CD45- fluorescein isothiocyanate (FITC). All antibodies were purchased from BD Biosciences (San Diego, CA). Cells were incubated for 1 h at 4 °C. Prior to antibody labeling, the cells were preincubated with 5% fetal bovine sera (FBS) for 10 min to block nonspecific binding. Cell suspensions were washed and resuspended in PBS for analysis on an LSRFortessa (BD Biosciences). Ten thousand events were acquired, and the acquisition analysis was performed using FlowJo 7.6.2. Positive staining was defined as the fluorescence emission that exceeded levels obtained by more than 99% of cells from the population stained with the corresponding negative controls. The isotype (negative) control used in this study was IgG1 PE-Cy5.5, IgG1-PE and IgG1- FITC (BD Biosciences).

Cell differentiation

**Adipogenic differentiation.** Adipogenic differentiation was performed according to [35] with minor modifications. Briefly, WT and mutant MSCs at passages 4–7 were plated at a density 20,000 cells/cm$^2$ in a 12-well plate in regular culture medium. At 90–100% confluence, the culture medium was replaced by adipogenic induction medium, including high-glucose DMEM, 10% FBS, 0.5 mM 3-isobutyl-1-methylxanthine (Sigma, cat # I5879), 100 μM indomethacin (Sigma, cat # I7378), 0.1 μM dexamethasone and 10 μg/ mL insulin. After 28 days, cells were fixed with 4% formaldehyde (FA) and immediately stained with the standard Oil-Red-O protocol. Control cells were kept in regular culture medium.

**Osteogenic differentiation.** Osteogenic differentiation was performed according to [35] with minor modifications. Briefly, WT and mutant cells at passages 4–7 were plated at a density of 10,000 cells/cm$^2$ in 12-well plates in regular culture medium. After 72 h, the culture medium was replaced by osteogenic differentiation medium containing high-glucose DMEM (Sigma), 10% FBS, 1 μM dexamethasone (Alfa Aesar, cat # A17590), 250 μM sodium ascorbate (Sigma, cat # A4034), and 10 mM β-glycerophosphate (Alfa Aesar, cat # L03425). The medium was changed every 3–4 days. Control cells were kept in regular culture medium. After 28 days of induction, cells were fixed in 4% FA and stained with standard Von Kossa Staining.

**Chondrogenic differentiation.** Chondrogenic differentiation was performed according to ref. [36] with minor modifications. Briefly, 2.5×10$^5$ WT and mutant cells were left aggregated in microwell plates and then provided with chondrogenic medium containing high-glucose DMEM, 10% FBS, 10 μg/ L TGF-β3, 0.1 μmol/ L dexamethasone, 50 μmol/ L vitamin C, and 6.25 mg/L insulin. The medium was changed every 3–4 days. Control cells were kept in regular culture medium. After 28 days of induction, cells were fixed in 4% formaldehyde, stained with toluidine blue for 2 min at room temperature and viewed by light microscopy.
Cholinergic-Like Neuron (ChLN) differentiation. ChLN differentiation was performed according to ref. [29]. WT and mutant MSCs were seeded at 1–1.5 x 10^4 cells/cm^2 in laminin-treated culture plates for 24 h in regular culture medium (RCm). Then, the medium was removed, and cells were incubated in minimal culture medium (hereafter MCM) containing low-glucose DMEM and 1% FBS or in cholinergic differentiation medium (Cholinergic-N-Run medium, hereafter Ch-N-Rm) containing DMEM/F-12 media 1:1 Nutrient Mixture (Gibco cat# 10565018), 10 ng/mL basic fibroblast growth factor (bFGF) recombinant human protein (Gibco Cat# 13256029), 50 μg/mL sodium heparin (Hep, Sigma-Aldrich cat# H3393), 0.5 μM all-trans retinoic acid, 50 ng/ml sonic hedgehog peptide (SHH, Sigma cat# SRP3156) and 1% FBS at 37°C for 7 days. After this process of transdifferentiation, the cells were labeled as WT PSEN1 or PSEN1 E280A ChLNs. Since Ch-N-Rm contains several factors that might interfere with the experiment interpretation and measurements, WT PSEN1 and PSEN1 E280A ChLNs (obtained after 7 days in Ch-N-Rm) were left in regular culture medium (RCm) for 0, 2 or 4 additional days, hereafter 0, 2, or 4 days of post transdifferentiation.

Immunofluorescence analysis
For the analysis of neural-, Alzheimer’s disease-, oxidative stress- and cell death-related markers, the cells treated under different conditions were fixed with cold ethanol (-20°C) for 20 min, followed by Triton X-100 (0.1%) permeabilization and 10% bovine serum albumin (BSA) blockage. Cells were incubated overnight with primary neural antibodies against glial fibrillary acidic protein (GFAP 1:200, cat# sc6170, Santa Cruz), microtubule-associated protein 2 (MAP2, 1:250, cat MA1-25044, Invitrogen), β-tubulin III (1:250, cat# G712 A, Promega) and choline-acetyltransferase (ChAT, 1:50, cat# AB144 P, Millipore); primary antibodies against APP751 and/or protein amyloid β_{1-42} (1:500; clone 6E10 cat# 803014, Biolegend), total TAU (1:500; t-Tau; cat# T6402, Sigma), and phospho-TAU (p-Tau, 1:500, Ser202/Thr205, cat# MN1020 (AT8), Thermo Fisher Scientific); and primary antibodies against oxidized DJ-1 (1:500; ox(Cys106)DJ1; spanning residue C_{106} of human PARK7/DJ1; oxidized to produce cysteine sulfonic (SO_3) acid; cat # MABN1773, Millipore). To assess cell death, we used primary antibodies against p53-upregulated modulator of apoptosis (1:500; PUMA, cat# ab-9643, Abcam), p53 (1:500; cat MA5-12453, Millipore), phospho-c-Jun (1:250; c-Jun (S63/73) cat# sc-16312, Santa Cruz), and caspase-3 (1:250; cat # AB3623, Millipore). After exhaustive rinsing, we incubated the cells with secondary fluorescent antibodies (DyLight 488 and 594 horse anti-rabbit, -goat and -mouse, cat DI 1094, DI 3088, and DI 2488, respectively) at 1:500. The nuclei were stained with 1 μM Hoechst 33342 (Life Technologies), and images were acquired on a Floyd Cells Imaging Station microscope.

Western blot analysis
Cells were incubated as described above, detached with 0.25% trypsin and lysed in 50 mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), and 0.1% sodium dodecyl sulfate and a protease inhibitor cocktail (Sigma-Aldrich). All lysates were quantified using the bicinchoninic acid assay (Thermo Scientific cat # 23225). Extracted samples (30 μg of proteins) were heated at 95°C for 5 min in 2 x SDS and 20x reducing agent (except for protein oxDJ-1) and loaded into 12% Bis/Tris gels at 120 V for 90 min, and the bands were transferred onto nitrocellulose membranes (Hybond-ECL, Amersham Biosciences) at 270 mA for 90 min using an electrophoretic transfer system (BIO-RAD) according to ref. [37] with minor modifications. The membranes were incubated overnight at 4°C with anti-GFAP, MAP2, β-tubulin III, ChAT, amyloid β_{1-42}, total TAU, phospho-TAU, ox(Cys_{106}) DJ1, PUMA, p53, p-c-Jun, and caspase-3 primary antibodies (1:5000). The anti-actin antibody
(1:1000, cat #MAB1501, Millipore) was used as an expression control. Secondary infrared antibodies (goat anti-rabbit IRDye® 680RD, cat #926–68071; donkey anti-goat IRDye® 680RD, cat # 926–68074; and goat anti mouse IRDye® 800CW, cat #926–32270; LI-COR Biosciences) at 1:1000 were used for western blotting analysis, and data were acquired using Odyssey software. To directly control the conformation-dependent differences among Aβ assemblies, we prepared a homogenous synthetic unaggregated (i.e., monomers) and large oligomeric Aβ42 assemblies according to ref. [38]. Briefly, after solubilization of the peptide (Sigma Cat #A9810) in DMSO, the “unaggregated” peptide was obtained by dissolving the DMSO-solubilized peptide in water and used immediately (0 days). To obtain the “large oligomers”, 10 mM Tris was added to DMSO-solubilized peptide solution and incubated it for 15 days at 4 °C. The determination of the aggregation state of Aβ42 was performed by Western analysis of SDS-PAGE as described above. The assessment was repeated three times in independent experiments.

**Mass spectrometry analysis**

Gel region between 60 and 125 kDa was excised from the experimental lane, cut into 1 x 1 mm cubes, incubated consequently with 10 mM dithiothreitol and 55 mM iodoacetamide in 100 mM ammonium bicarbonate, and dehydrated with acetonitrile. Then, the proteins were in-gel digested overnight at 37 °C with LysC protease (Promega, Mannheim). The resulting peptide mixture was extracted twice with exchange of 5% formic acid and 100% acetonitrile, the extracts pulled together and dried down. The peptides were re-suspended in 25 μl of 5% formic acid and 5 μl were taken for LC-MS/MS analysis. The analysis was performed on a nano-UPLC Ultimate 3000 interfaced on-line to a Q-Exactive HF Hybrid Quadrupole-Orbitrap mass spectrometer (both Thermo Fisher Scientific, Bremen). The UPLC system was equipped with Acclaim PepMap™ 100 75 μm x 2 cm trapping column and 75 μm x 15 cm separating column packed with 3 μm diameter C18 particles (Thermo Fisher Scientific, Bremen). Peptides were separated using 180 min linear gradient (solvent A– 0.1% formic acid in water, solvent B– 0.1% formic acid in neat acetonitrile). Spectra were acquired in DDA mode using top 20 method. Spectra were then converted into (.mgf) format and searched human sequences in the UniProt database (January 2020) using MASCOT software (version 2.2.04) and against human Amyloid-beta precursor protein (ACC No P05067) without enzyme specificity. Mass tolerance was set on 5 ppm and 0.025 Da for precursor and fragment ions respectively; variable modification–Cysteine carbamidomethyl and propionamide, methionine oxidation, protein N-terminal acetyl. The result of the database search was evaluated by Scaffold software (v.4.7.5, Proteome Software, Portland) and the spectra matched Amyloid-beta precursor protein also manually inspected. To investigate the presence of Aβ42, the spectra were acquitted in DDA targeted mode using masses of C- and N-terminal peptides which are unique for 671–713 fragment, and then processed by SkyLine software.

**Analysis of cells**  
**Evaluation of intracellular hydrogen peroxide (H2O2) by fluorescence microscopy.** To determine the levels of intracellular H2O2, we used 2',7'-dichlorofluorescein diacetate (5 μM, DCFH2-DA; Invitrogen). hWJ-MSCs or ChLNes were left in RM for 0, 2 and 4 days. Then, the cells (5 x 10^3) were incubated with the DCFH2-DA reagent for 30 min at 37 °C in the dark. Cells were then washed, and DCF fluorescence intensity was determined by analysis of fluorescence microscopy images. The assessment was repeated three times in independent experiments. The nuclei were stained with 0.5 μM Hoechst 33342 (2.5 μM) staining compound. The assessment was repeated three times in independent experiments blind to experimenter.
Evaluation of intracellular hydrogen peroxide (H\(_2\)O\(_2\)) by flow cytometry. H\(_2\)O\(_2\) was determined with 2',7'-dichlorofluorescein diacetate (1 μM, DCFH\(_2\)-DA). ChLNs were left in regular medium (RCm) for 0, 2 and 4 days. Then, the cells (1x10\(^5\)) were incubated with DCFH\(_2\)-DA reagent for 30 min at 37 °C in the dark. Cells were then washed, and DCF fluorescence was determined using an LSRFortessa (BD Biosciences). The assessment was repeated 3 times in independent experiments. Quantitative data and figures were obtained using FlowJo 7.6.2 Data Analysis Software. The assessment was repeated three times in independent experiments blind to experimenter and flow cytometer analyst.

Analysis of mitochondrial membrane potential (Δ\(\Psi\)m) by fluorescence microscopy. The hWJ-MSCs or ChLNs were left in regular culture medium (RCm) for 0, 2 and 4 days. Then, the cells (5 x 10\(^3\)) were incubated with the passively diffusing and active mitochondria-accumulating dye deep-red MitoTracker compound (20 nM, final concentration) for 20 min at RT in the dark (Invitrogen, cat # M22426). Cells were then washed twice with PBS. MitoTracker fluorescence intensity was determined by analysis of fluorescence microscopy images. The assessment was repeated three times in independent experiments. The nuclei were stained with 0.5 μM Hoechst 33342 (2.5 μM) staining compound. The assessment was repeated three times in independent experiments blind to experimenter and flow cytometer analyst.

Analysis of mitochondrial membrane potential (Δ\(\Psi\)m) by flow cytometry. ChLNs were left in regular medium for 0, 2 and 4 days. Then, the cells (1x10\(^5\)) were incubated for 30 min at RT in the dark with MitoTracker (20 nM, final concentration). The cells were analyzed using an LSRFortessa (BD Biosciences). The experiment was performed three times in independent experiments, and 10,000 events were acquired for analysis. Quantitative data and figures were obtained using FlowJo 7.6.2 Data Analysis Software. The assessment was repeated three times in independent experiments blind to experimenter and flow cytometer analyst.

Determination of DNA fragmentation by flow cytometry. DNA fragmentation was determined using a hypotonic solution of PI. Cells entering the cellular cycle phase sub-G\(_0\) were identified as those undergoing apoptosis. ChLNs were left in regular medium for 0, 2 and 4 days. Then, the cells (1x10\(^5\)) were detached, washed twice with PBS (pH 7.2) and stored in 95% ethanol overnight at -20 °C. The cells were washed and incubated in 400 μL solution containing propidium iodide (PI; 50 μg/ml), RNase A (100 μg/ mL), EDTA (50 mM), and Triton X-100 (0.2%) for 60 min at 37 °C. The cell suspension was analyzed for PI fluorescence using an Epics XL flow cytometer (Beckman Coulter). DNA fragmentation was assessed 3 times in independent experiments. Quantitative data and figures from the sub-G\(_0\)/G\(_1\) population were obtained using FlowJo 7.6.2 Data Analysis Software. The assessment was repeated three times in independent experiments blind to experimenter and flow cytometer analyst.

Acetylcholinesterase activity measurement. We determined the acetylcholinesterase (AChE) activity using the AChE Assay Kit (Abcam, Cat# ab138871) according to the manufacturer’s protocol. Briefly, ChLNs at days 0, 2 and 4 of post differentiation were detached with 0.25% trypsin and mechanically lysed by freezing/sonication. Lysates were centrifuged at 18,894 x g for 15 min, and supernatants were used for protein quantification by the BCA method (see above) and the detection of AChE activity. AChE degrades the neurotransmitter acetylcholine (ACh) into choline and acetic acid. We used the DTNB (5,5'-dithiobis(2-nitrobenzoic acid)) reagent to quantify the thiocholine produced from the hydrolysis of acetylthiocholine by AChE. The absorption intensity of the DTNB adduct was used to measure the amount of thiocholine formed, which was proportional to AChE activity. We read the absorbance in a microplate reader at ~410 nm. The data obtained were compared to the standard curve values, and the AChE amounts (mU) were normalized to protein values (mU/ mg protein). The assessment was repeated three times in independent experiments blind to experimenter.
Measurement of Aβ1–42 peptide in culture medium. The level of Aβ1–42 peptide was measured according to a previous report [39] with minor modifications. Briefly, WT and PSEN1 E280A ChLNs were left in regular medium for 0, 2 and 4 days. Then, 100 μl of conditioned medium was collected, and the levels of secreted Aβ1–42 peptides were determined by a solid-phase sandwich ELISA (Invitrogen, Cat# KHB3544) following the manufacturer’s instructions. The assessment was repeated three times in independent experiments blind to experimenter.

Intracellular calcium imaging. Intracellular calcium (Ca^{2+}) concentration changes evoked by cholinergic stimulation were assessed according to refs. [40, 41] with minor modifications. For the measurement, the fluorescent dye Fluo-3 (Fluo-3 AM; Thermo Fisher Scientific, cat: F1242) was employed. The dye was dissolved in DMSO (1 mM) to form a stock solution. Before the experiments, the stock solution was diluted in neuronal buffer solution (NBS buffer: 137 mM NaCl, 5 mM KCl, 2.5 mM CaCl_{2}, 1 mM MgCl_{2}, pH 7.3, and 22 mM glucose). The working concentration of the dye was 2 μM. The WT and PSEN1 E280A ChLNs were incubated for 30 min at 37 °C with the dye-containing NBS and then washed five times. Intracellular Ca^{2+} transients were evoked by acetylcholine (1 mM final concentration) at 0, 2 and 4 days post differentiation. The measurements were carried out using the 100x objective of the microscope. Several regions of interest (ROIs) were defined in the visual field of the camera. One of the ROIs was cell-free, and the fluorescence intensity measured here was considered background fluorescence (F_{bg}). The time dependence of the fluorescence emission was acquired, and the fluorescence intensities (hence the Ca^{2+} levels) were represented by pseudocolors. To calculate the changes of the average Ca^{2+}-related fluorescence intensities, the F_{bg} value was determined from the cell-free ROI, and then the resting fluorescence intensities (F_{rest}) of the cell-containing ROIs were obtained as the average of the points recorded during a period of 10 s prior to the addition of acetylcholine. The peaks of the fluorescence transients were found by calculating the average of four consecutive points and identifying those points that gave the highest average value (F_{max}). The amplitudes of the Ca^{2+}-related fluorescence transients were expressed relative to the resting fluorescence (ΔF/F) and were calculated by the following formula: ΔF/F = (F_{max}-F_{rest})/(F_{rest}-F_{bg}). For the calculation of the fluorescence intensities, ImageJ was used. The terms fluorescence intensity was used as an indirect indicator of intracellular Ca^{2+} concentration. The assessment was repeated three times in independent experiments blind to experimenter.

JNK inhibition experiment. The ChLNs were left in regular medium for 0, 2 and 4 days alone or co-incubated with the anthrapyrazolone JNK inhibitor SP600125 (1 μM final concentration). This compound competes with ATP to inhibit the phosphorylation of c-JUN. After this time, cells were evaluated for p-TAU and t-TAU protein expression by immunofluorescence, as described above. The assessment was repeated three times in independent experiments blind to experimenter.

Photomicrography and image analysis

Light microscopy photographs were taken using a Zeiss Axioskop 50 Fluorescence Microscope equipped with a Canon PowerShot G5 digital camera (Zeiss Wöhlk-Contact-Linsen, Gmb Schörikirchen, Germany), and fluorescence microscopy photographs were taken using a Zeiss Axioskop 50 Fluorescence Microscope equipped with a Zeiss AxioCam Cm1 and (Zeiss Wöhlk-Contact-Linsluoreen, Gmb Schörikirchen, Germany) and Floyd Cells Imaging Station microscope. Fluorescence images were analyzed by ImageJ software (http://imagej.nih.gov/ij/). The figures were transformed into 8-bit images, and the background was subtracted. The cellular measurement regions of interest (ROIs) were drawn around the nucleus (for the
case of transcription factors and apoptosis effectors) or over all cells (for cytoplasmic probes), and the fluorescence intensity was subsequently determined by applying the same threshold for cells in the control and treatment conditions. Mean fluorescence intensity (MFI) was obtained by normalizing total fluorescence to the number of nuclei.

Data analysis
In this experimental design, a vial of MSCs was thawed, cultured and the cell suspension was pipetted at a standardized cellular density of $2.6 \times 10^4 \text{ cells/cm}^2$ into different wells of a 24-well plate. Cells (i.e., the biological and observational unit [42]) were randomized to wells by simple randomization (sampling without replacement method), and then wells (i.e., the experimental units) were randomized to treatments by similar method. Experiments were conducted in triplicate wells. The data from individual replicate wells were averaged to yield a value of $n = 1$ for that experiment and this was repeated on three occasions blind to experimenter and/or flow cytometer analyst for a final value of $n = 3$ [42]. Based on the assumptions that the experimental unit (i.e. the well) data comply with independence of observations, the dependent variable is normally distributed in each treatment group (Shapiro-Wilk test), and there is homogeneity of variances (Levene’s test), the statistical significance was determined by a One-way analysis of variance (ANOVA) followed by Tukey’s post hoc comparison calculated with GraphPad Prism 5.0 software. Differences between groups were only deemed significant when a $p$-value of $<0.05$ (*), $<0.001$ (**), and $<0.001$ (***). All data are illustrated as the mean ± S.D.

Results
PSEN1 E280A and wild-type WJ-MSCs show similar phenotype, immunophenotype, lineage differentiation and transdifferentiation
We first evaluated whether the PSEN1 E280A mutation affects the capacity of MSCs to generate mesodermal and ectodermal lineages through differentiation and transdifferentiation, respectively. Therefore, WJ-MSCs were isolated from ten umbilical cords of volunteers according to standard procedures [43], and PCR-RFLP electrophoretic profile analysis identified one umbilical cord sample out of ten as a carrier of the mutation PSEN1 c.839A > C, p.E280A (PSEN1 E280A MSCs, S1 Fig). Then, PSEN1 E280A MSCs and wild-type WJ-MSCs (WT PSEN1 MSCs) were further cultured and characterized for morphological, karyotypic, immuno-phenotypic features and differentiation capabilities. As shown in Fig 1, WT PSEN1 and PSEN1 E280A MSCs displayed the typical colony-forming units (Fig 1A and 1B), adherent growth, and fibroblast-like cellular morphology (Fig 1C and 1D). Karyotype analysis showed no chromosomal alterations (Fig 1E and 1F), and APOE genotyping analysis showed that PSEN1 E280A cells had the APOE*3/4 genotype and WT PSEN1 cells had the APOE*3/3 genotype (S2 Fig). Flow cytometry analysis showed that both wild-type and mutant MSCs were positive (>95% of positive cells) for mesenchymal associated markers CD73, CD90 and CD9 (Fig 1G and 1H), but negative (<5% of positive cells) for hematopoietic cell surface antigens CD34/CD45. WT and PSEN1 E280A MSCs cultured in adipogenic, osteogenic, or chondrogenic induction medium differentiated into adipocytes (Fig 1J and 1P), osteoblasts (Fig 1L and 1R), and chondrocytes (Fig 1N and 1T), respectively, while MSCs cultured in regular culture medium were undifferentiated (Fig 1I, 1O, 1K, 1Q, 1M and 1S).

Additionally, MSCs were transdifferentiated into cholinergic-like neurons (ChLNs) from WJ-MSCs using a new method [29]. As shown in Fig 2, WT PSEN1 and PSEN1 E280A WJ-MSCs cultured in minimal culture medium (MCM) for 7 days expressed basal levels of protein MAP2 (Fig 2A and 2B) and β Tub III (Fig 2A and 2C) and undetectable levels of
Fig 1. Characterization of WT PSEN1 and PSEN1 E280A WJ-MSCs. (A-B) Representative images showing the colony-forming units and (C-D) adherent growth and fibroblast-like morphology typical of WJ-MSCs. (E-F) Karyotype analysis performed at passage 2 showing chromosomal normality (46XX). (G-H) Flow cytometry analyses showing the percentage of double-positive CD9/CD73/CD90/CD34 and CD45 WJ-MSCs. (I, O) Oil-Red-O negatively stained undifferentiated WJ-MSCs grown on regular culture medium. (J, P) Oil-Red-O positively stained adipocytes differentiated from WJ-MSCs showing intracellular red lipidic vacuoles. (K, Q) Von Kossa negatively stained undifferentiated WJ-MSCs grown on regular culture medium. (L, R) Von Kossa positively stained osteoblasts differentiated from WJ-MSCs showing silver intracellular precipitates. (M, S) Toluidine blue negatively stained undifferentiated WJ-MSCs grown on regular culture medium. (N, T) Toluidine blue positively stained chondrocytes differentiated from WJ-MSCs showing extracellular glycoprotein matrix. Image magnification, 400x. The images represent 1 out of 3 independent experiments. 

https://doi.org/10.1371/journal.pone.0221669.g001
Fig 2. Cholinergic-like neurons differentiate from WT PSEN1 and PSEN1 E280A WJ-MSCs. WT PSEN1 and PSEN1 E280A WJ-MSCs were cultured in cholinergic differentiation medium as described in the Materials and Methods section for 7 days. After this time, the proteins in the extracts were blotted with primary antibodies against MAP2, β-tubulin III, GFAP, ChAT and actin proteins. The intensities of the western blot bands shown in (A) were measured (B, C, D, E) by an infrared imaging system (Odyssey, LI-COR), and the intensity was normalized to that of actin. (F) Measurements of acetylcholinesterase activity in WT PSEN1 and PSEN1 E280A ChLNs after 7 days of transdifferentiation. (G-J) Cells were double stained as indicated in the figure with primary antibodies against β-
GFAP (Fig 2A and 2D) and ChAT (Fig 2A and 2E). As expected, when the cells were exposed to cholinergic-N-Run medium (Ch-N-Rm) for 7 days [29], the levels of protein MAP2 (Fig 2A and 2B), βTub III (Fig 2A and 2C) and ChAT (Fig 2A and 2E) were significantly higher than those in cells exposed to MCm. Noticeably, ChLNs remained negative for the specific glial cell lineage marker GFAP (Fig 2A and 2D). These observations were confirmed by immunofluorescence (Fig 2G–2J). Because the enzyme AChE catalyzes the breakdown of the neurotransmitter acetylcholine (ACh, [44]), we evaluated whether ChLNs expressed a catalytically functional AChE enzyme. As shown in Fig 2F, the AChE enzyme presented basal activity in WJ-MSCs under MCm culture conditions (~8 ± 1.2 mU/mg protein), while the AChE enzyme activity was significantly higher (at least a 3-fold increase) in both control and mutant ChLNs (~26 ± 1.6 mU/mg protein). Remarkably, there was no significant difference in AChE enzymatic activity (p < 0.05) between WT and PSEN1 E280A ChLNs (at day 0 of post differentiation).

WT and PSEN1 E280A WJ-MSCs show similar levels of intracellular APP / Aβ42, oxidized DJ-1, mitochondrial membrane potential (ΔΨm) and Reactive Oxygen Species (ROS)

Next, we evaluated whether the PSEN1 E280A mutation induced overproduction of APP/Aβ42 and OS, and alterations in ΔΨm and ROS production in MSCs. After 7 days of culture in MCm, MSCs were left in RCm for 0, 2 and 4 additional days. Western blot measurements and immunofluorescence analysis revealed that both WT and PSEN1 E280A MSCs displayed undetectable levels of intracellular APP / Aβ42 and oxidized DJ-1 at days 0, 2 and 4 (S3A–S3J Fig). Moreover, both WT and PSEN1 E280A MSCs displayed normal ΔΨm (S4A Fig), undetectable levels of ROS (S4B Fig) and no changes in DNA content (S4C Fig) at days 0, 2 and 4 in RCm according to flow cytometry (S4A–S4C Fig) and DCF/MitoTracker fluorescence (S4D–S4K Fig).

PSEN1 E280A Cholinergic-Like Neurons (ChLNs) show high levels of intracellular sAPPβf, oxidized DJ-1, reactive oxygen species (ROS), loss of mitochondrial membrane potential (ΔΨm) and DNA fragmentation, but none of those markers are detected in WT PSEN1 ChLNs

The above observations prompted us to evaluate the same cell parameters in ChLNs. We initially verify that the antibody clone 6E10 recognizes Aβ monomers as well as large aggregates of Aβ42 and APP. Effectively, the antibody recognized the “unaggregated” (monomers), and large aggregates forms of synthetic Aβ42 peptide (Fig 3A). The WT PSEN1 and PSEN1 E280A ChLNs (obtained after 7 days in Ch-N-Rm) were left in regular culture medium (RCm) for 0, 2 and 4 additional days post transdifferentiation (hereafter labelled as 0, 2, or 4). Western blot also revealed that WT PSEN1 ChLNs displayed undetectable levels of intracellular APP/ Aβ42 aggregates (Fig 3A and 3B) and oxidized DJ-1 (Fig 3A and 3C), whereas flow cytometry showed no loss of ΔΨm (Fig 4A–4C) and no ROS generation (Fig 4D–4F) at any time tested. However, PSEN1 E280A ChLNs exhibited significantly higher levels of intracellular APP/ Aβ42 aggregates (Fig 3A and 3B) and oxidized DJ-1 (Fig 3A and 3C) and lower ΔΨm than WT PSEN1 ChLNs at days 2 and 4 (Fig 4B and 4C). These observations were confirmed by
Fig 3. PSEN1 E280A Cholinergic-Like Neurons (ChLNs) show high levels of intracellular sAPPβ and oxidized DJ-1. Synthetic unaggregated (i.e., monomers) and large oligomeric Aβ42 assemblies were prepared as described in Material and Methods section according to Ref. [38]. The ChLNs were obtained as follows. After 7 days of transdifferentiation, WT PSEN1 and PSEN1 E280A ChLNs were left in regular culture medium (RCm) for 0 and 4 days, as indicated in the figure. After this time, the proteins in the extracts were blotted with primary antibodies against Aβ42, oxDJ-1Cys106 and actin proteins. The intensities of the western blot bands shown in (A) were measured (B, C) by an infrared imaging system (Odyssey, LI-COR), and the intensity was normalized to that of actin. Additionally, cells were double stained as indicated in the figure (D-I) with primary antibodies against APP751/ Aβ42 (red; D'-I') and oxDJ-1Cys106 (green; D'-I'). The nuclei were stained with Hoechst 33342 (blue; D'-I'). (K) Quantification of Aβ42 fluorescence intensity. Data are expressed as the mean ± SD; *p<0.05; **p<0.01; ***p<0.001. The blots and figures represent 3 independent experiments (Repeat 1, R2, and R3). The arrowhead represents APP and/or Aβ42 aggregates. Image magnification, 200x; inset magnification, 800x. LE = light exposure; DE = dark exposure.

https://doi.org/10.1371/journal.pone.0221669.g003
immunofluorescence microscopy (Figs 3D–3K and 4J'–4O'). To confirm the identity of the intracellular APP/\(\alpha\)42 aggregates displayed in the Western blot (Fig 3A, arrowhead), we used LC-MS/MS technique. The LC-MS/MS analysis identified two peptides LPTTAASTP-DAVDK (S5A Fig) and AVIQHFQEK (S5B Fig) that showed high homology with APP fragments (e.g., APP714, APP733, APP751, APP752, S5C Fig), hereafter sAPP\(\beta\)f. No \(\alpha\)42 fragment was identified in the interrogated gel region. Interestingly, PSEN1 E280A ChLNs showed high levels of ROS production as early as day 0, that is, at day 7 of transdifferentiation (Fig 4D, 4M” and 4Q) and at day 2 post transdifferentiation (Fig 4E, 4N” and 4Q), but ROS were severely reduced at day 4 (Fig 4F, 4O” and 4Q). Furthermore, both WT and PSEN1 E280A ChLNs exhibited a typical quiescent cell cycle (i.e., phase G\(_0\), Fig 4G–4I) and showed similar numbers of cells in the SubG\(_0\) population at day 0 (Fig 4G); nonetheless, the SubG\(_0\) population was significantly elevated in PSEN1 E280A ChLNs at day 2 (~15% compared to that in WT cells; Fig 4H) and day 4 (~12% compared to WT cells; Fig 4I) according to propidium iodide (PI) fluorescence analysis.

**PSEN1 E280A ChLNs display activation of p53, PUMA, c-JUN and CASPASE-3**

Next, we wanted to investigate whether the intracellular sAPP\(\beta\)f induced cell death signaling in PSEN1 ChLNs. Therefore, we used the transcription factors p53 and c-JUN, pro-apoptotic BH3-only protein PUMA, and protease CASPASE-3 as cell death markers to examine the pro-death activity of sAPP\(\beta\)f in ChLNs over time. As shown in Fig 5, while WT PSEN1 ChLNs showed no detectable levels of apoptogenic proteins at any time tested (Fig 5A–5E), the PSEN1 E280A ChLNs displayed significant detection of c-JUN (at day 0, 2 and 4, Fig 5A and 5B), p53 (at day 2 and 4, Fig 5A and 5C), PUMA (at day 4, Fig 5A and 5D) and CASP-3 (at day 4,
PSEN1 E280A Cholinergic-like neurons show early oxidative stress and pathological markers

Fig 5. PSEN1 E280A ChLNs display activation of p53, PUMA, c-JUN and CASPASE-3. After 7 days of transdifferentiation, WT PSEN1 and PSEN1 E280A ChLNs were left in regular culture medium (RCm) for 0, 2 and 4 additional days, as indicated in the figure. After this time, the proteins in the extracts were blotted with primary antibodies against phosphorylated c-JUN (c-JUN), p53, PUMA, CASPASE-3 (CASP-3) and actin proteins. The intensities of the western blot bands shown in (A) were measured (B, C, D and E) by an infrared imaging system (Odyssey, LI-COR), and the intensity was normalized to that of actin. Additionally, after 4 days, ChLNs were double stained as indicated in the figure (F–I) with primary antibodies against p53 (green; F' and G'), PUMA (red; F' and G'), c-JUN (green; H' and I') and CASP-3 (red; H' and I'). The nuclei were stained with Hoechst 33342 (blue; F'''-I'''').

Quantification of p53 (J), PUMA (K), c-JUN (L) and CASP-3 (M) fluorescence intensity. Data are expressed as the mean ± SD; * p<0.05; ** p<0.01; *** p<0.001. The blots and figures represent 1 out of 3 independent experiments. Image magnification, 200x.

https://doi.org/10.1371/journal.pone.0221669.g005

These observations were confirmed by immunofluorescence analysis at day 4 (Fig 5F–5M).

PSEN1 E280A ChLNs show reduced functional response to Acetylcholine (ACh), low acetylcholinesterase activity, and generation of high levels of extracellular Aβ42 peptide

We further investigated whether WT and PSEN1 E280A ChLNs responded to ACh stimuli as an evaluation of cholinergic neuronal Ca^{2+} responsiveness and functionality [29]. To this aim,
we simultaneously measured the secreted levels of Aβ42 and evaluated the response of ChLNs to ACh. ELISA revealed that both WT PSEN1 and PSEN1 E280A ChLNs secreted similarly low levels of extracellular Aβ42 at days 0 and 2, but at day 4, PSEN1 E280A ChLNs showed significantly higher extracellular levels of Aβ42 compared to PSEN1 WT ChLNs (~3.2-f.i., Fig 6A). For functional analysis, both control and mutant PSEN1 ChLN cultures were puffed with ACh (1 mM final concentration) into a bath solution. As expected, ACh induced a transient elevation of intracellular Ca2+ in WT PSEN1 ChLNs at day 0 (Fig 6B and 6D), 2 (Fig 6E and 6G) and 4 post-transdifferentiation (Fig 6H and 6J). The average fluorescence change (ΔF/F) was 6.4 ± 0.6, 6.4 ± 0.7 and 5.9 ± 1.4-fold, respectively, with a mean duration of 40 ± 10 s (n = 20 ChLN cells imaged, N = 3 dishes) according to cytoplasmic Ca2+ responses to Fluo-3-mediated imaging. Interestingly, PSEN1 E280A ChLNs showed higher intracellular Ca2+ in response to ACh treatment at day 0 (Fig 6C and 6D) and 2 (Fig 6F and 6G) than WT PSEN1 ChLNs (Fig 6D and 6G). The average fluorescence change (ΔF/F) was 4.6 ± 1.2 and 5.1 ± 1.1-fold, respectively, with a mean duration of 40 ± 10 s (n = 20 ChLN cells imaged, N = 3 dishes). Nevertheless, we found a significant difference in the ΔF/F response (ΔF/F = 1.1 ± 0.75, p < 0.001) in PSEN1 E280A ChLNs exposed to ACh at 4 days post differentiation (Fig 6I and 6J) compared to that in WT ChLNs (Fig 6H and 6J).

The above findings compelled us to evaluate whether ChLNs expressed a catalytically functional acetylcholinesterase (AChE) enzyme at similar times post of transdifferentiation. As shown in Fig 6K, the AChE enzyme showed similar catalytic activity at days 2 and 4 in both WT PSEN1 and PSEN1 E280A ChLNs. However, the AChE enzyme activity in PSEN1 E280A ChLNs was significantly lower (at least 5-fold) than that in WT PSEN1 ChLNs at day 4.

PSEN1 E280A ChLNs induce phosphorylation of TAU protein

Several experimental data support Aβ-induced TAU pathology (e.g., ref. [45]), however no data is available to determine whether sAPPβf can induce protein TAU phosphorylation. We thus evaluated whether PSEN1 E280A ChLNs display abnormal levels of phosphorylated TAU protein at residues Ser202 and Thr205, two well-known hyperphosphorylated epitopes involved in AD pathology [46]. To this end, wild-type and mutant ChLNs were left in regular culture medium (RCm) for 0, 2 and 4 days. Then, the ratio of phosphorylated TAU (p-TAU)/total TAU (t-TAU) was determined by western blot and immunofluorescence imaging analyses. As shown in Fig 7, while WT PSEN1 ChLNs showed no phosphorylation of TAU protein according to western blot (Fig 7A and 7B) and immunofluorescence microscopy (Fig 7C–7E’ and 7I), PSEN1 E280A ChLNs presented an increase in the p-TAU/ t-TAU ratio at 4 days post transdifferentiation (Fig 7F, 7B, 7F’–7H’ and 7I). JNK has been suggested to phosphorylate TAU at the Ser202/Thr205 epitopes [47]. Therefore, we determined whether JNK was implicated in TAU phosphorylation in ChLNs. To this end, PSEN1 E280A ChLNs were incubated with the JNK inhibitor SP600125 for 0, 2 and 4 days. Notably, the p-TAU/ t-TAU ratio remained unaltered at 0 (Fig 7J, 7K, 7O’ and 7R), 2 (Fig 7J, 7K, 7P’ and 7R) and 4 days post differentiation (Fig 7J, 7K, 7Q’ and 7R).

Discussion

Currently, the neuropathology of AD includes extracellular deposits of Aβ in plaques, intracellular neurofibrillary tangles comprising hyperphosphorylated TAU, synaptic dysfunction, and neuronal death. In an effort to explain such observations, several theories have been proposed [48]; however, the amyloid cascade hypothesis has prevailed for more than 25 years [49]. The Aβ hypothesis postulates that an imbalance in the production of extracellular Aβ42 plaques by mutations in at least three genes (e.g., APP, PSEN1; PSEN2) is an early initiating factor in AD.
Fig 6. PSEN1 E280A ChLNs show a reduced functional response to Acetylcholine (ACh), low acetylcholinesterase activity and high levels of extracellular Ab42 peptide. After 7 days of transdifferentiation, WT PSEN1 and PSEN1 E280A ChLNs were left in regular culture medium for 0, 2 and 4 days, as indicated in the figure. (A) ELISA quantification of extracellular Ab42 peptide in supernatants. Time-lapse images (0, 10, 20, 30, 40 s) of Ca2+ fluorescence in WT PSEN1 and PSEN1 E280A ChLNs after 0 (B-C), 2 (E-F) and 4 days (H-I) in response to ACh treatment. ACh was puffed into the culture at 10 s (arrow). Then, the Ca2+ fluorescence of the cells was monitored at the indicated times. Color contrast indicates fluorescence intensity: dark blue < light blue < green < yellow < red. (D, G, J) Normalized mean fluorescence signal (ΔF/F) over time from the cells indicating temporal cytoplasmic Ca2+ elevation in response to ACh treatment. (K) Measurement of acetylcholinesterase activity at 0, 2 and 4 days post transdifferentiation. Data are presented as the means ± SD. *p<0.05; **p<0.01; ***p<0.001. The histograms and figures represent 1 out of 3 independent experiments. Image magnification, 400x.

https://doi.org/10.1371/journal.pone.0221669.g006
Fig 7. PSEN1 E280A ChLNs induce phosphorylation of TAU protein. After 7 days of transdifferentiation, WT PSEN1 and PSEN1 E280A ChLNs were left untreated (A-I) or treated with 1 μM JNK inhibitor SP600125 (J-R) in regular culture medium for 0, 2 and 4 days as indicated in the figure. After this time, the proteins in the extracts were blotted with primary antibodies against phosphorylated TAU (p-TAU), total TAU (t-TAU) and actin proteins. The intensities of the western blot bands shown in (A or J) were measured (B or K) by an infrared imaging system (Odyssey, LI-COR), and the p-TAU/t-TAU ratio was normalized to that of actin. Additionally, ChLNs were double stained as indicated in the figure (C-H or L-Q) with primary antibodies against p-TAU (green; C’-H’ or L’-Q’) and t-TAU (red; C”-H” or L”-Q”). The nuclei were stained with Hoechst 33342 (blue; C”-H” or L”-Q”). (I and R) Quantification of the p-TAU/t-TAU fluorescence ratio. Data are expressed as the mean ± SD; *p<0.05; **p<0.01; ***p<0.001. The blots and figures represent 1 out of 3 independent experiments. Image magnification, 200x.

https://doi.org/10.1371/journal.pone.0221669.g007
However, experimental therapies targeting Aβ have thus far been unsuccessful [50]. Several factors have probably contributed to the failures in AD drug development, including unsuitable preclinical research models that do not fully recapitulate the human disease; consequently, druggable targets remain missing [51]. Furthermore, the mechanism(s) by which hAPP/ Aβ42 might induce toxicity is not yet fully established. Because UC-MSCs possess plasticity properties enabling them to transdifferentiate into non-mesenchymal lineages, they provide a unique opportunity to study the effect of PSEN1 mutations in neuronal cells. Most importantly, MSC-derived neurons are natural, non-genetically modified cells of the FAD PSEN1 mutation. Here, we used UC-MSCs bearing the mutation PSEN1 E280A for the first time and found that the mutation alters none of the typical MSC characteristics, such as colony-forming capacity, fibroblast-like morphology, immunophenotype and/or ability to differentiate or transdifferentiate into ChLNs. Furthermore, we did not detect any APP/ Aβ42 produced by the cells or any other cellular alterations (e.g., ROS production, mitochondria depolarization, and oxidation of stress sensor DJ-1) in mutant MSCs. These observations suggest that the PSEN1 E280A mutation might not affect the physiology of the multipotent MS cells at this stage of development.

In this study, we report for the first time that ChLNs derived from hMSCs carrying the PSEN1 E280A mutation recapitulate typical pathologic features of AD at 4 days post transdifferentiation, i.e., eleven days of culture (7 days in Ch-N-Rm and 4 days in RCm) including increased secretion of Aβ42, intracellular accumulation of sAPPβ, and Tau phosphorylation. Furthermore, PSEN1 E280A ChLNs not only show OS and apoptosis markers but also display Ca2+ flux dysregulation and altered acetylcholinesterase activity. Our data provide evidence that intracellular sAPPβ specifically induces neurotoxicity through a temporal and sequential order of molecular events in PSEN1 E280A ChLNs. In agreement with commercial laboratory Western blot data (https://www.biolegend.com/en-us/products/anti-beta-amyloid-1-16-antibody-10998), the antibody 6E10 recognized monomers (4 kDa), and aggregated (~100 kDa) synthetic Aβ42, and high molecular weight APP/ Aβ42 (~100 kDa) in PSEN1 E280A ChLNs. Interestingly, no Aβ42 monomers were detected in mutant ChLNs. These observations suggested aggregation of APP. In agreement with this assumption, mass spectrometry (MS) analysis identified several APP fragments (e.g., APP714, APP733, APP751, APP752, collectively named sAPPβ) but no Aβ42 fragment was present at the gel region of HMW proteins (60–120 kDa). Outstandingly, the sAPP fragments can be generated not only by the β-secretase but also by the δ-secretase, η-secretase or Meprin β [4]. Taken together these observations suggest that sAPP fragments rather than Aβ42 are accumulating early in the PSEN1 E280A cholinergic neurons. Accordingly, we found intracellular sAPPβ accumulation in ChLNs after 7 days of transdifferentiation (day 0), at which time fully developed ChLNs were obtained [29]. Whether intracellular APP fragments build up because full length APP processing is altered and consequently some APP fragments remain intracellular leading to cell death require further investigation. However, recent data support this view. Indeed, it has been shown that hAPP overexpression causes Aβ-independent neuronal death in olfactory sensory neurons via intrinsic apoptosis pathway [5, 6]. In contrast, others have found that the PSEN1 L166P and G384A mutations cause relocalization of γ-secretase, which significantly promotes the generation of intracellular long Aβ42 [52]. Although it is not yet known whether the PSEN1 E280A mutation induces relocalization of γ-secretase, similar to PSEN1 mutations, our data suggest that the PSEN1 E280A mutation strongly enhances intraneuronal sAPPβ aggregates in ChLNs. These results support the view that intracellular accumulation of sAPPβ is the earliest event in the development of the neuropathological changes of AD [53]. Since the PSEN1 E280A mutation might represent a typical trans-dominant negative mutation on γ-secretase [15, 16], we do not discard the possibility that APP-derived intracellular Aβ42 aggregates might...
be a late event in the process of neurodegeneration [7, 54, 55]. Interestingly, we simultaneously found a significant increase in DCF fluorescent-positive cells, DJ-1 Cys\(^{106}\)-sulfonate (DJ-1 Cys\(^{106}\)SO\(_3\)), which is the most sensitive thiol group towards H\(_2\)O\(_2\) reactivity [56], and activation of transcription factor c-JUN in PSEN1 E280A ChLNs. These observations suggest that sAPP\(^{β}\) (aggregates) > H\(_2\)O\(_2\) > oxDJ-1Cys\(^{106}\)-SO\(_3\) and c-JUN are the earliest events detectable in PSEN1 E280A ChLNs. These findings imply that hAPP and/or sAPP\(^{β}\) (high molecular weight aggregates) can trigger events related to oxidative stress and cell death [5, 6]. How then does intracellular sAPP\(^{β}\) generate H\(_2\)O\(_2\)? Several lines of evidence for the intracellular toxicity of APP have been suggested, including inhibition of mitochondrial import channels (e.g., TOM40 and TIM23), impairment of mitochondrial transport (e.g., Cytochrome c oxidase), and disruption the electron transfer [57]. Whatever the mechanism, we demonstrated for the first time that sAPP\(^{β}\) endogenously produces H\(_2\)O\(_2\) in PSEN1 E280A ChLNs. Because H\(_2\)O\(_2\) can function as a second messenger [58], it might also activate other redox proteins, such as apoptosis-signal regulating kinase 1 (ASK-1, [59], which in turn directly or indirectly activate other signaling pathways, e.g., JNK/c-JUN [60]. We found that sAPP\(^{β}\) induced phosphorylation of c-JUN [61], p53 and PUMA in PSEN1 E280A ChLNs. Notably, c-JUN- and p53-dependent apoptosis is triggered by transactivation of the pro-apoptotic gene PUMA [62–64]. Remarkably, JNK can also stabilize and activate p53 [65]. Taken together, these results suggest that sAPP\(^{β}\) > H\(_2\)O\(_2\) activates a cascade of events leading to the JNK > c-JUN, p53 > PUMA pathway. Although PUMA has been shown to cooperate with direct activator proteins (e.g., BAX) to promote mitochondrial outer membrane permeabilization (MOMP) and apoptosis [66], the exact mechanism by which MOMP occurs is not fully understood [67]. Interestingly, PSEN1 E280A ChLNs showed loss of ΔΨ\(_m\) concomitant with overexpression of CASPASE-3 and fragmentation of nuclei at day 4 post transdifferentiation. These observations suggest that mitochondria play an important role in intracellular sAPP\(^{β}\)-induced apoptosis in mutant ChLNs. However, whether ΔΨ\(_m\) dysfunction is a consequence of a direct effect of intracellular sAPP\(^{β}\) on the organelle or whether the damage is the result of the impact of PUMA on mitochondria is an unresolved issue. Our findings suggest that both sAPP\(^{β}\) / PUMA might separately or jointly damage ΔΨ\(_m\). Taken together, these data indicate that sAPP\(^{β}\) induce a cascade of events in PSEN1 E280A ChLNs through the H\(_2\)O\(_2\) signaling pathway involving CASP-3, as an end executer protein, and DNA fragmentation of nuclei, all indicative of apoptosis. Taken together, these data comply with the idea that intraneuronal accumulation of the APP fragments (sAPP\(^{β}\)) are the first step of a lethal cascade in FAD neurons.

Neuronal calcium (Ca\(^{2+}\)) dyshomeostasis has been proposed to play a crucial role in AD disease progression [68]. However, the mechanisms of Ca\(^{2+}\) dysregulation are not clear. In contrast to Demuro and Parker [69], who found that intracellular Aβ42 oligomers disrupted cellular Ca\(^{2+}\) regulation, we observed no Ca\(^{2+}\) dysregulation in PSEN1 E280A ChLNs evaluated at 0, 2, and 4 days post transdifferentiation. This discrepancy can be explained by differences in experimental methodology. Whereas those authors elucidated the actions of intracellular Aβ42 by imaging Ca\(^{2+}\) responses to injections of Aβ42 oligomers into Xenopus oocytes, we directly imaged Ca\(^{2+}\) responses to endogenously generated intracellular APP in mutant ChLNs. Under the present experimental conditions, we concluded that intracellular sAPP\(^{β}\) did not affect Ca\(^{2+}\) flux in PSEN1 E280A ChLNs. However, increasing evidence has shown that extracellular Aβ specifically interacts with nAChRs, resulting in Ca\(^{2+}\) dysregulation [70]. We found that the PSEN1 E280A ChLN response to ACh was significantly reduced by day 4 post transdifferentiation. Notably, Aβ has been shown to directly affect α7 nicotinic ACh receptor (α7 nAChR) function by acting as an agonist (~100 nM) and a negative modulator (at high concentrations) [71]. Consistent with this view, we confirmed that PSEN1 E280A ChLNs secreted aberrant amounts of Aβ42 (e.g., ~2500-f.i.) compared to WT PSEN1 ChLNs. These
observations confirm that overproduction of extracellular Aβ42 is a paramount feature of the majority of PSEN1 mutations in vitro and in vivo [9], including the E280A mutation [25]. Despite these observations, further investigation is required to determine whether α7 nAChRs specifically are affected by Aβ42 in PSEN1 E280A ChLNs. In contrast to others (e.g., [72]), our observations do not support the common view that extracellular Aβ is capable of increasing neuronal Ca2+ flux through Aβ42-forming pores. However, we do not discard the possibility that given a longer incubation time, Aβ42 could affect Ca2+ flux via Aβ42-forming pores in PSEN1 E280A ChLNs. Taken together, our data suggest that extracellular Aβ42 might bind to nAChRs in PSEN1 E280A ChLNs, affecting neuronal Ca2+ flux.

The accumulation of hyperphosphorylated TAU in neurons leads to neurofibrillary degeneration in AD [73]. Mounting evidence suggests that TAU pathogenesis is promoted by Aβ42 [74,75]. We found that PSEN1 E280A ChLNs showed hyperphosphorylation of TAU protein. In fact, PSEN1 E280A ChLNs exhibited a significantly higher p-TAU/ t-TAU ratio than WT PSEN1 ChLNs at 4 days post transdifferentiation. Because absence of Aβ42, these observations imply that sAPPβ rather than Aβ42 signaling precedes TAU phosphorylation [75, 76] in PSEN1 E280A ChLNs. These findings suggest that sAPPβ accumulation might affect TAU pathology. However, the molecular link between sAPPβ and TAU is still not yet completely defined. In agreement with others [77], our data suggest that JNK is a strong candidate TAU kinase involved in the hyperphosphorylation of TAU in PSEN1 E280A ChLNs. This assumption is supported by two observations. First, JNK phosphorylates TAU at Ser202/Thr205 [47], two phosphorylation epitopes identified in the present study. Second, PSEN1 E280A ChLNs exposed to the JNK inhibitor SP600125 significantly reduced TAU phosphorylation. Although we do not discard the possibility that other kinases might be implicated in TAU pathology (e.g., LRRK2, GSK-3, Cdk5), our findings suggest that JNK plays a key role in TAU hyperphosphorylation in PSEN1 E280A ChLNs. Our results suggest that PSEN1 E280A-induced neural alterations may precede Aβ42 deposition and that those alterations represent longstanding effects of intracellular sAPPβ toxicity and possibly even developmental changes. The molecular alterations might start when neurons develop into neuron-specific cholinergic-type cells or may even exist at birth. These findings may explain why functional and structural brain changes manifest in children (9–17 years old) and young individuals (18–26 years old) who are carriers of the PSEN1 E280A mutation [79, 80]. Furthermore, these observations suggest that intracellular sAPPβ toxicity is an early and slowly progressive process that might damage neuronal cells in a TAU-dependent and independent fashion (OS, ΔΨm shutdown, apoptosis and intraneuronal Ca2+ dysregulation) more than two decades before the stage of dementia [10, 81].

**Conclusion**

We demonstrate that intracellular accumulation of sAPPβ, generation of H2O2, oxidation of the DJ-1 protein (DJ-1 Cys106-SO3), and activation of the pro-apoptosis protein c-JUN were the earliest cellular changes in PSEN1 E280A ChLNs (obtained after 7 days in Ch-N-Rm (i.e., day 0 in RCm), Fig 8 step 1, s2, s3, s4/s5). These changes were followed by the activation of pro-apoptosis proteins p53 (s6) and PUMA (s7), loss of mitochondria membrane potential (ΔΨm, s8), activation of CASP-3 (s9), fragmentation of nuclei (s10), and complete expression of markers of apoptosis (at day 4 post transdifferentiation in RCm). These biochemical abnormalities were found concomitant with irregular secretion of Aβ42 (day 4, s11), Ca2+ flux dysregulation (s12), diminished secretion of AChE (s13), and hyperphosphorylation of TAU protein (day 4, s14). Therefore, our data support the view that FAD PSEN1 E280A cholinergic
neuronal pathology is instigated by early intracellular accumulation of sAPPβf [55, 82]. These findings raise the question of whether strategies to remove extracellular Aβ42 such as immunotherapy [83] should be complemented with treatments to remove intracellular sAPPβf [84] and OS (i.e., H₂O₂) to avoid apoptosis and TAU pathology and treatment with nAChR.
agonists to increase neuronal functionality. The present findings naturally (i.e., not genetically manipulated) recapitulated for the first time the neuropathological features of FAD PSEN1 E280A. We anticipate that the present in vitro model will inspire new and innovative therapies for early onset PSEN1 E280A patients. Despite the fact that the mutation PSEN1 E280A is 100% penetrant in those individuals bearing such mutation, and given that our findings are based on ChLNs obtained from a single PSEN1 E280A MSCs, the conclusions from such analyses require verification through additional studies with larger sample size.

Supporting information

S1 Fig. Identification of PSEN1 genotype in WT PSEN1 and PSEN1 E280A in WJ-MSCs. The PSEN1 E280A mutation was detected as described in Materials and Methods section. According to different mobility electrophoretic patterns, samples were classified as wild-type (WT) or mutant PSEN1 E280A when compared to PSEN1 E280A carrier (positive case NB code#18233) or wild type PSEN1 genotype (NB code#18574). Abbreviations: TBC# = tissue bank code number; F = female, M = male; (+) = positive; (-) = negative; numbers on the left are molecular size markers expressed in bp.

(TIF)

S2 Fig. Apolipoprotein E (APOE) genotype in WT PSEN1 and PSEN1 E280A (n = 1) WJ-MSCs. Electrophoretic separation of HhaI fragments after gene amplification of DNA from WT PSEN1 and PSEN1 E280A WJ-MSCs. The DNA band pattern was determined according to ref. [29]. Numbers on the left are molecular size markers expressed in bp. Abbreviations: TBC# = tissue bank code number; F = female, M = male.

(TIF)

S3 Fig. WT PSEN1 and PSEN1 E280A WJ-MSCs show similar levels of intracellular APP/Aβ42 and oxidized DJ-1. WT PSEN1 and PSEN1 E280A WJ-MSCs were cultured in MCm for 7 days, and then cultured for 4 additional days in regular culture medium (RCm). Then, the proteins in the extracts and control extracts were blotted with primary antibodies against Aβ42, oxDJ-1Cys106 and actin proteins. The intensities of the western blot bands shown in (A) were measured (B, C) by an infrared imaging system (Odyssey, LI-COR), and the intensity was normalized to that of actin. Control lysates were included to validate the results. Additionally, after 0, 2 and 4 days, WJ-MSCs were double stained as indicated in the figure (D-I) with primary antibodies against Aβ42 (red; D'-I') and oxDJ-1Cys106 (green; D'-I'). The nuclei were stained with Hoechst 33342 (blue; D''-I''). (J) Quantification of Aβ42 fluorescence intensity. (K) Quantification of oxDJ-1Cys106 fluorescence as MFI. Data are expressed as the mean ± SD; *p<0.05; **p<0.01; ***p<0.001. The blots and figures represent 1 out of 3 independent experiments. Image magnification, 200x.

(TIF)

S4 Fig. WT PSEN1 and PSEN1 E280A WJ-MSCs show similar levels of mitochondrial membrane potential (Δψm), intracellular reactive oxygen species (ROS) and DNA fragmentation. Representative histograms showing DiOC6(3)low (A), DCF+ (B) and SubG1 (C) populations from WT PSEN1 (blue) and PSEN1 E280A (Red) WJ-MSCs after 7 days in MCm plus 4 days in RCm. Representative MitoTracker (D'-I'), DCF (D''-I''), Hoechst (D'''-I'''') and merged (D-I) pictures of WT PSEN1 and PSEN1 E280A WJ-MSCs after 0, 2 and 4 days in RCm. (J) Quantification of MitoTracker fluorescence intensity. (K) Quantification of DCF fluorescence intensity. Data are expressed as the mean ± SD; *p<0.05; **p<0.01; ***p<0.001. The histograms and figures represent 1 out of 3 independent experiments. Image
magnification, 200x. (TIF)

S5 Fig. Mascot Search Results of (A) MS/MS fragmentation of LPTTAASTPDAVDK, and (B) MS/MS fragmentation of AVIQHFQEK. (C) List of proteins identified in the PAGE gel region of high molecular weight between 60 and 125 kDa. (PDF)

S1 File. (ZIP)

S1 Data. (XLSX)

Acknowledgments

We greatly acknowledge KA Herrera-Galeano (Nurse), F Piedrahita (Nurse), I Lopez (Psychologist) and AA Espinosa-Rojas (MD) for technical support for obtaining human umbilical cord tissue at Hospital San Juan de Dios, Yarumal, Colombia. We specially acknowledge the newborns’ parents for human umbilical cord tissue. We thank Dr. A Shevchenko (Head of Mass Spectrometry, Max Plank Institute of Molecular Cell Biology and Genetics, Dresden-Germany) for LC-MS/MS analysis.

Author Contributions

Conceptualization: Carlos Velez-Pardo, Marlene Jimenez-Del-Rio.

Data curation: Viviana Soto-Mercado, Miguel Mendivil-Perez, Carlos Velez-Pardo, Marlene Jimenez-Del-Rio.

Formal analysis: Viviana Soto-Mercado, Miguel Mendivil-Perez, Carlos Velez-Pardo.

Funding acquisition: Francisco Lopera, Marlene Jimenez-Del-Rio.

Investigation: Viviana Soto-Mercado, Miguel Mendivil-Perez.

Methodology: Viviana Soto-Mercado, Miguel Mendivil-Perez.

Project administration: Marlene Jimenez-Del-Rio.

Resources: Francisco Lopera, Marlene Jimenez-Del-Rio.

Supervision: Carlos Velez-Pardo, Francisco Lopera.

Writing – original draft: Carlos Velez-Pardo, Marlene Jimenez-Del-Rio.

Writing – review & editing: Viviana Soto-Mercado, Miguel Mendivil-Perez, Carlos Velez-Pardo, Francisco Lopera, Marlene Jimenez-Del-Rio.

References

1. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018; 25(1):59–70. Epub 2017/09/06. https://doi.org/10.1111/ene.13439 PMID: 28872215.

2. Douchamps V, Mathis C. A second wind for the cholinergic system in Alzheimer’s therapy. Behav Pharmacol. 2017; 28(2 and 3-Spec issue):112–23. Epub 2017/02/28. https://doi.org/10.1097/FBP.0000000000000300 PMID: 28240674.

3. Perl DP. Neuropathology of Alzheimer’s disease. Mt Sinai J Med. 2010; 77(1):32–42. Epub 2010/01/27. https://doi.org/10.1002/msj.20157 PMID: 20101720.
4. Andrew RJ, Kellett KA, Thinakaran G, Hooper NM. A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis. J Biol Chem. 2016; 291(37):19235–44. Epub 2016/07/31. https://doi.org/10.1074/jbc.R116.746032 PMID: 27474742.

5. Cheng N, Jiao S, Gunasekara T, Bai L, Belluscio L. APP Overexpression Causes Abeta-Independent Neuronal Death through Intrinsic Apoptosis Pathway. eNeuro. 2016; 3(4). Epub 2016/08/16. https://doi.org/10.1523/eneuro.0150-16.2016 PMID: 27517085.

6. Cheng N, Cai H, Belluscio L. In vivo olfactory model of APP-induced neurodegeneration reveals a reversible cell-autonomous function. J Neurosci. 2011; 31(39):13669–704. Epub 2011/10/01. https://doi.org/10.1523/JNEUROSCI.1714-11.2011 PMID: 21957322.

7. Takahashi RH, Nagao T, Gouras GK. Plaque formation and the intraneuronal accumulation of beta-amyloid in Alzheimer’s disease. Pathol Int. 2017; 67(4):185–93. Epub 2017/03/07. https://doi.org/10.1111/pin.12520 PMID: 28261941.

8. Steiner H, Fukumori A, Tagami S, Okochi M. Making the final cut: pathogenic amyloid-β peptide generation by γ-secretase. Cell Stress. 2018; 2(11):292–310. https://doi.org/10.15698/cst2018.11.162 PMID: 31225454.

9. Sun L, Zhou R, Yang G, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by γ-secretase. Proc Natl Acad Sci U S A. 2017; 114(4):E476–e85. Epub 2016/12/09. https://doi.org/10.1073/pnas.1618657114 PMID: 27930341.

10. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, Jaramillo-Elorza MC, Moreno S, Aguierre-Acevedo DC, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet Neurol. 2011; 10(3):213–20. https://doi.org/10.1016/S1474-4422(10)70323-9 PMID: 21296022.

11. Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997; 277(10):793–9. Epub 1997/03/12. PMID: 9052708.

12. Sepulveda-Falla D, Glatzel M, Lopera F. Phenotypic profile of early-onset familial Alzheimer’s disease caused by presenilin-1 E280A mutation. J Alzheimers Dis. 2012; 32(1):1–12. https://doi.org/10.3233/JAD-2012-120907 PMID: 22766738.

13. Fuller JT, Cronin-Golomb A, Gatchel JR, Norton DJ, Guzman-Velez E, Jacobs HIL, et al. Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer’s Disease: A Comprehensive Review of the Colombian Kindred. J Prev Alzheimers Dis. 2019; 6(2):112–20. Epub 2019/02/14. https://doi.org/10.1016/j.jalz.2019.02.006 PMID: 30756118.

14. Lall MA, Cox HC, Arcila ML, Cadavid L, Moreno S, Garcia G, et al. Origin of the PSEN1 E280A mutation causing early-onset Alzheimer’s disease. Alzheimers Dement. 2014; 10(Suppl):S277–S83.e10. Epub 2013/11/19. https://doi.org/10.1016/j.jalz.2013.09.005 PMID: 24239249.

15. Heilig EA, Gutti U, Tai T, Shen J, Kieleher RJ 3rd. Trans-dominant negative effects of pathogenic PSEN1 mutations on γ-secretase activity and Abeta production. J Neurosci. 2013; 33(28):11606–17. Epub 2013/07/12. https://doi.org/10.1523/JNEUROSCI.0954-13.2013 PMID: 23843529.

16. Zhou R, Yang G, Shi Y. Dominant negative effect of the loss-of-function γ-secretase mutants on the wild-type enzyme through heterooligomerization. Proc Natl Acad Sci U S A. 2012; 109(10):12731–6. Epub 2011/10/29. https://doi.org/10.1073/pnas.1115761109 PMID: 22078389.

17. Lemere CA, Lopera F, Kosik KS, Lendon CL, Osaa J, Saito TC, et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med. 1996; 2(10):1146–50. https://doi.org/10.1038/nm1096-1146 PMID: 8837617.

18. Velez-Pardo C, Arellano JI, Cardona-Gomez P, Jimenez Del Rio M, Lopera F, De Felipe J. CA1 hippocampal neuronal loss in familial Alzheimer’s disease presenilin-1 E280A mutation is related to epilepsy. Epilepsia. 2004; 45(7):751–6. Epub 2004/07/03. https://doi.org/10.1111/j.0013-5850.2004.55403.x PMID: 15230697.

19. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, et al. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: a cross-sectional study. Lancet Neurol. 2012; 11(12):1057–65. https://doi.org/10.1016/S1474-4422(12)70227-2 PMID: 23137949.

20. Quiroz YT, Sperling RA, Norton DJ, Baena A, Arboleda-Velasquez JC, Cosio D, et al. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol. 2018; 75(5):548–56. Epub 2018/02/13. https://doi.org/10.1001/jamaneurol.2017.4907 PMID: 29435558.

21. Kumar K, Kumar A, Keegan RM, Deshmukh R. Recent advances in the neurobiology and neuropsychology of Alzheimer’s disease. Biomed Pharma. 2018; 98:297–307. Epub 2017/12/24. https://doi.org/10.1016/j.biopharm.2017.12.053 PMID: 29274586.
22. Oksanen M, Petersen AJ, Naumenko N, Puttonen K, Lehtonen S, Gubert Olive M, et al. PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer’s Disease. Stem Cell Reports. 2017; 9(6):1885–97. Epub 2017/11/21. https://doi.org/10.1016/j.stemcr.2017.10.016 PMID: 29153989.

23. Ochalek A, Mihalik B, Avci HX, Chandrasekaran A, Teglas A, Bock I, et al. Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation. Alzheimers Res Ther. 2017; 9(1):90. Epub 2017/12/02. https://doi.org/10.1186/s13195-017-0317-z PMID: 29192129.

24. Yang J, Zhao H, Ma Y, Shi G, Song J, Tang Y, et al. Early pathogenic event of Alzheimer’s disease documented in iPSCs from patients with PSEN1 mutations. Oncotarget. 2017; 8(5):7900–13. Epub 2016/12/08. https://doi.org/10.18632/oncotarget.13776 PMID: 27926491.

25. Mendivil-Perez M, Velez-Pardo C, Kosik KS, Lopera F, Jimenez-Del-Rio M. iPSCs-derived nerve-like cells from familial Alzheimer’s disease PSEN1 E280A reveal increased amyloid-beta levels and loss of the Y chromosome. Neurosci Lett. 2019; 703:111–8. Epub 2018/03/25. https://doi.org/10.1016/j.neulet.2019.03.032 PMID: 30904577.

26. Cheng H, Ghetu N, Wallace C, Wei F, Liao S. The Impact of Mesenchymal Stem Cell Source on Proliferation, Differentiation, Immunomodulation and Therapeutic Efficacy. J Stem Cell Res Ther. 2014; 4(10):1–8. https://doi.org/10.4172/2157-7633.1000237.

27. Zhang HT, Fan J, Cai YQ, Zhao SJ, Xue S, Lin JH, et al. Human Wharton’s jelly cells can be induced to differentiate into growth factor-secreting oligodendrocyte progenitor-like cells. Differentiation. 2010; 79(1):15–20. Epub 2009/10/08. https://doi.org/10.1016/j.diff.2009.09.002 PMID: 19800163.

28. Bonilla-Porras AR, Velez-Pardo C, Jimenez-Del-Rio M. Fast transdifferentiation of human Wharton’s jelly mesenchymal stem cells into neurospheres and nerve-like cells. J Neurosci Methods. 2017; 282:52–60. Epub 2017/03/14. https://doi.org/10.1016/j.jneumeth.2017.03.005 PMID: 28286110.

29. Mendivil-Perez M, Velez-Pardo C, Jimenez-Del-Rio M. Direct transdifferentiation of human Wharton’s jelly mesenchymal stromal cells into cholinergic-like neurons. J Neurosci Methods. 2019; 312:126–38. Epub 2018/11/26. https://doi.org/10.1016/j.jneumeth.2018.11.019 PMID: 30472070.

30. Choi J, Lee S, Mallard W, Clement K, Tagliazucchi GM, Lim H, et al. A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs. Nat Biotechnol. 2015; 33(11):1179–81. Epub 2015/10/27. https://doi.org/10.1038/nbt.3388 PMID: 26501951.

31. Song L, Tsai AC, Yuan X, Bejoy J, Sart S, Ma T, et al. Neural Differentiation of Spheroids Derived from Human Induced Pluripotent Stem Cells-Mesenchymal Stem Cells Coculture. Tissue Eng Part A. 2018; 24(11–12):915–29. Epub 2017/11/22. https://doi.org/10.1089/ten.tea.2017.0403 PMID: 29160172.

32. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet. 1995; 11(2):219–22. Epub 1995/10/01. https://doi.org/10.1038/ng1095-219 PMID: 7550356.

33. III, JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990; 31(3):545–8. Epub 1990/03/01. PMID: 2341813.

34. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006; 1(5):2315–9. Epub 2007/04/05. https://doi.org/10.1038/nprot.2006.339 PMID: 17406473.

35. Huang S, Feng C, Wu Y, Yang S, Ma K, Wu X, et al. Dissimilar characteristics of umbilical cord mesenchymal stem cells from donors of different ages. Cell Tissue Bank. 2013; 14(3):907–13. Epub 2013/03/12. https://doi.org/10.1007/s10561-013-9364-2 PMID: 23475054.

36. Xie J, Du X, Li K, Chen Y, Guan Y, Zhao X, et al. Construction of engineered corpus cavernosum with primary mesenchymal stem cells in vitro. Sci Rep. 2017; 7(1):18053. Epub 2017/12/24. https://doi.org/10.1038/s41598-017-18129-9 PMID: 29273785.

37. Sandoval KE, Farr SA, Banks WA, Crider AM, Morley JE, Witt KA. Somatostatin receptor subtype-4 agonist NNC 26–9100 mitigates the effect of soluble Abeta(42) oligomers via a metalloproteinase-dependent mechanism. Brain Res. 2013; 1520:145–56. Epub 2013/09/27. https://doi.org/10.1016/j.brainres.2013.05.006 PMID: 23669069.

38. Stine WB, Jungbauer L, Yu C, LaDu MJ. Preparing Synthetic Aβ in Different Aggregation States. Methods Mol Biol. 2011; 670:13–32. https://doi.org/10.1007/978-1-60761-744-0_2 PMID: 20967580.

39. Armojo E, Gonzalez C, Shahnavaz M, Flores A, Davis B, Soto C. Increased susceptibility to Abeta toxicity in neuronal cultures derived from familial Alzheimer’s disease (PSEN1-A246E) induced pluripotent stem cells. Neurosci Lett. 2017; 639:74–81. Epub 2016/12/31. https://doi.org/10.1016/j.neulet.2016.12.060 PMID: 28094781.

40. Pap P, Koszeghy A, Szucs G, Rusznak Z. Cytoplasmic Ca(2+) concentration changes evoked by cholinergic stimulation in primary astrocyte cultures prepared from the rat cochlear nucleus. Hear Res. 2009; 255(1–2):73–83. Epub 2009/06/06. https://doi.org/10.1016/j.heares.2009.05.006 PMID: 19497596.
41. Sekiguchi-Tonosaki M, Obata M, Haruki A, Himi T, Kosaka J. Acetylcholine induces Ca2+ signaling in chicken retinal pigmented epithelial cells during dedifferentiation. Am J Physiol Cell Physiol. 2009; 296 (5):C1195–206. Epub 2009/02/27. https://doi.org/10.1152/ajpcell.00423.2008 PMID: 19244481.

42. Lazic SE, Clarke-Williams CJ, Munafò MR. What exactly is 'N' in cell culture and animal experiments? PLoS Biol. 2018; 16(4):e2005282. Epub 2018/04/05. https://doi.org/10.1371/journal.pbio.2005282 PMID: 29617358.

43. Mendivil-Perez M, Velez-Pardo C, Jimenez-Del-Rio M. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson’s Disease. Neurochem Res. 2016; 41(10):2675–92. Epub 2016/07/11. https://doi.org/10.1007/s11064-016-1982-1 PMID: 27394417.

44. Taylor P, Camp S, Radić Z. Acetylcholinesterase. In: Squire LR, editor. Encyclopedia of Neuroscience. Oxford: Academic Press; 2009. p. 5–7.

45. Stancu IC, Vasconcelos B, Jimenez-Del-Rio M. Models of beta-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. Mol Neurodegener. 2014; 9:51. Epub 2014/11/20. https://doi.org/10.1186/1750-1326-9-51 PMID: 25407337.

46. Zhou Y, Shi J, Hu W, Guan Z, Gong CX, et al. Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease. Front Aging Neurosci. 2018; 10:27. Epub 2018/02/24. https://doi.org/10.3389/fnagi.2018.00027 PMID: 29472853.

47. Simic G, Babić Leko M, Wray S, Harrison C, Delalle I, Jovanović-Milosevic N, et al. Tau Protein Hyper-phosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules. 2016; 6(1):6. Epub 2016/01/12. https://doi.org/10.3390/biom6010006 PMID: 26751493.

48. Du X, Wang X, Geng M. Alzheimer's disease hypothesis and related therapies. Transl Neurodegener. 2018; 7:2. Epub 2018/02/10. https://doi.org/10.1186/s40035-018-0107-y PMID: 29423193.

49. Hardy J. The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the "amyloid cascade hypothesis". Fiebs j. 2017; 284(7):1040–4. Epub 2017/01/06. https://doi.org/10.1111/febs.14004 PMID: 28054745.

50. Doig AJ, Del Castillo-Frias MP, Berthoumieu O, Tarus B, Nasica-Labouze J, Sterpone F, et al. Why Is Research on Amyloid-beta Failing to Give New Drugs for Alzheimer’s Disease? ACS Chem Neurosci. 2017; 8(7):1435–7. Epub 2017/04/05. https://doi.org/10.1021/acschemneuro.7b00188 PMID: 28566203.

51. Khachaturian AS, Hayden KM, Mielke MM, Tang Y, Lutz MW, Gustafson DR, et al. Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework. Alzheimers Dement. 2018; 14(5):532–4. Epub 2018/04/15. https://doi.org/10.1016/j.jalz.2018.03.003 PMID: 29653605.

52. Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK, et al. Restricted Location of PSEN2/gamma-Secretase Determines Substrate Specificity and Generates an Intracellular Abeta Peptide. Cell. 2016; 166(1):193–208. Epub 2016/06/14. https://doi.org/10.1016/j.cell.2016.05.020 PMID: 27293189.

53. Lauritzen I, Pardossi-Piquard R, Bourgeais A, Becot A, Checler F. Does Intraneuronal Accumulation of Carboxyl-terminal Fragments of the Amyloid Precursor Protein Trigger Early Neurotoxicity in Alzheimer’s Disease? Curr Alzheimer Res. 2019; 16(5):493–7. Epub 2019/03/26. https://doi.org/10.2174/156720501666190325092841 PMID: 30907322.

54. Lauritzen I, Pardossi-Piquard R, Bourgeais A, Becot A, Checler F. Does Intraneuronal Accumulation of Carboxyl-terminal Fragments of the Amyloid Precursor Protein Trigger Early Neurotoxicity in Alzheimer’s Disease? Curr Alzheimer Res. 2019; 16(5):493–7. Epub 2019/03/26. https://doi.org/10.2174/156720501666190325092841 PMID: 30907322.

55. Wirths O, Mullhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide—the first step of a fatal cascade. J Neurochem. 2004; 91(3):513–20. Epub 2004/01/16. https://doi.org/10.1111/j.1471-4159.2004.02737.x PMID: 15485483.

56. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci. 2007; 8(7):499–509. Epub 2007/06/07. https://doi.org/10.1038/nrn2168 PMID: 17551515.

57. Linum T, Kimata J, Taira T, Ariga H, Niki E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2004; 317(3):722–8. https://doi.org/10.1016/j.bbrc.2004.03.110 PMID: 15081400.

58. Spuch C, Otolano S, Navarro C. New insights in the amyloid-Beta interaction with mitochondria. J Aging Res. 2012; 2012:324968. https://doi.org/10.1155/2012/324968 PMID: 22823685.

59. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998; 17(9):2596–606. https://doi.org/10.1093/emboj/17.9.2596 PMID: 9564042.
60. Reddy CE, Albanito L, De Marco P, Aiello D, Maggiolini M, Napoli A, et al. Multisite phosphorylation of c-Jun at threonine 91/93/95 triggers the onset of c-Jun pro-apoptotic activity in cerebellar granule neurons. Cell Death Dis. 2013; 4:e852. Epub 2013/10/12. https://doi.org/10.1038/cddis.2013.381 PMID: 24113186.

61. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci. 2001; 21(19):7551–60. Epub 2001/09/22. https://doi.org/10.1523/JNEUROSCI.21-19-07551.2001 PMID: 11567045.

62. Lu H, Hou G, Zhang Y, Dai Y, Zhao H. c-Jun transactivates Puma gene expression to promote osteoarthritis. Mol Med Rep. 2014; 9(5):1606–12. Epub 2014/02/26. https://doi.org/10.3892/mmr.2014.1981 PMID: 24566851.

63. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001; 7(3):673–82. Epub 2001/07/21. https://doi.org/10.1016/s1097-2765(01)00213-1 PMID: 11463391.

64. Nakano K, Voussden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001; 7(3):683–94. Epub 2001/07/21. https://doi.org/10.1016/s1097-2765(01)00214-3 PMID: 11463392.

65. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci U S A. 1998; 95(18):10541–6. PMID: 9724739.

66. Hikisz P, Kilianska ZM. PUMA, a critical mediator of cell death—one decade on from its discovery. Cell Mol Biol Lett. 2012; 17(4):646–69. Epub 2012/09/25. https://doi.org/10.2478/s11658-012-0032-5 PMID: 23001513.

67. Pena-Blanco A, Garcia-Saez AJ, Bax, Bak and beyond—mitochondrial performance in apoptosis. Febs J. 2018; 285(3):416–31. Epub 2017/07/30. https://doi.org/10.1111/febs.14186 PMID: 28755482.

68. Briggs CA, Chakraborty S, Stutzmann GE. Emerging pathways driving early synaptic pathology in Alzheimer’s disease. Biochem Biophys Res Commun. 2017; 483(4):988–97. Epub 2016/09/24. https://doi.org/10.1011/jnc.12837 PMID: 25059095.

69. Demuro A, Parker I. Cytotoxicity of intracellular abeta42 amyloid oligomers involves Ca2+ release from the endoplasmic reticulum by stimulated production of inositol trisphosphate. J Neurosci. 2013; 33(9):3824–33. Epub 2013/03/01. https://doi.org/10.1523/JNEUROSCI.4367-12.2013 PMID: 23447594.

70. Ju Y, Asahi T, Sawamura N. Arctic mutant Abeta40 aggregates on alpha7 nicotinic acetylcholine receptors and inhibits their functions. J Neurochem. 2014; 131(5):667–74. Epub 2014/07/26. https://doi.org/10.1111/jnc.12387 PMID: 25059095.

71. Lasala M, Fabiani C, Corradi J, Antollini S, Bouzat C. Molecular Modulation of Human alpha7 Nicotinic Receptor by Amyloid-beta Peptides. Front Cell Neurosci. 2019; 13:37. Epub 2019/02/26. https://doi.org/10.3389/fncel.2019.00037 PMID: 30800059.

72. Kandel N, Zheng T, Huo Q, Tatulian SA. Membrane Binding and Pore Formation by a Cytotoxic Fragment of Amyloid beta Peptide. J Phys Chem B. 2017; 121(45):10293–305. Epub 2017/10/19. https://doi.org/10.1021/acs.jpcb.7b07002 PMID: 29039658.

73. Avila J. Our Working Point of View of Tau Protein. J Alzheimers Dis. 2018; 62(3):1277–85. Epub 2017/10/19. https://doi.org/10.3233/JAD-170600 PMID: 29038830.

74. Zheng WH, Bastianetto S, Menningen F, Ma W, Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 2002; 115(1):201–11. Epub 2002/10/29. https://doi.org/10.1016/s0306-4522(02)00404-9 PMID: 12401334.

75. Hu X, Li X, Zhao M, Gottesdiener A, Luo W, Paul S. Tau pathogenesis is promoted by Abeta1-42 but not Abeta1-40. Mol Neurodegener. 2014; 9:52. Epub 2014/11/25. https://doi.org/10.1186/1750-1326-9-52 PMID: 25417177.

76. Welikovitch LA, Do Carmo S, Magloczky Z, Szocsics P, Loke J, Freund T, et al. Evidence of intraneuronal Abeta accumulation preceding tau pathology in the entorhinal cortex. Acta Neuropathol. 2018; 136(6):901–17. Epub 2018/10/27. https://doi.org/10.1007/s00401-018-1922-z PMID: 30362029.

77. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci. 2009; 29(28):9078–89. Epub 2009/07/17. https://doi.org/10.1523/JNEUROSCI.1071-09.2009 PMID: 19605645.

78. Yarza R, Vela S, Solas M, Ramirez MJ. c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer’s Disease. Front Pharmacol. 2015; 6:321. Epub 2016/01/23. https://doi.org/10.3389/fphar.2015.00321 PMID: 26793112.

79. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease
in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012; 11(12):1048–56. Epub 2012/11/10. https://doi.org/10.1016/S1474-4422(12)70228-4 PMID: 23137948.

80. Quiroz YT, Schultz AP, Chen K, Protas HD, Brickhouse M, Fleisher AS, et al. Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study. JAMA Neurol. 2015; 72(8):912–9. Epub 2015/06/30. https://doi.org/10.1001/jamaneurol.2015.1099 PMID: 26121081.

81. Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207–16. Epub 2013/01/22. https://doi.org/10.1016/S1474-4422(12)70291-0 PMID: 23332364.

82. Cline EN, Bicca MA, Viola KL, Klein WL. The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade. J Alzheimer Dis. 2018; 64(s1):S567–s610. Epub 2018/05/31. https://doi.org/10.3233/JAD-179941 PMID: 29843241.

83. Cehlar O, Skrabana R, Revajova V, Novak M. Structural aspects of Alzheimer’s disease immunotherapy targeted against amyloid-beta peptide. Bratisl Lek Listy. 2018; 119(4):201–4. Epub 2018/04/18.

84. Chun YS, Kwon OH, Oh HG, Cho YY, Yang HO, Chung S. Justicidin A Reduces beta-Amyloid via Inhibiting Endocytosis of beta-Amyloid Precursor Protein. Biomol Ther (Seoul). 2019; 27(3):276–82. Epub 2018/10/20. https://doi.org/10.4062/biomolther.2018.112 PMID: 30332887.